OXAZOLAM

Details

Stereochemistry	MIXED
Molecular Formula	C18H17ClN2O2
Molecular Weight	328.793
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1CN2CC(=O)NC3=C(C=C(Cl)C=C3)C2(O1)C4=CC=CC=C4

InChI

InChIKey=VCCZBYPHZRWKFY-UHFFFAOYSA-N

InChI=1S/C18H17ClN2O2/c1-12-10-21-11-17(22)20-16-8-7-14(19)9-15(16)18(21,23-12)13-5-3-2-4-6-13/h2-9,12H,10-11H2,1H3,(H,20,22)

HIDE SMILES / InChI

Molecular Formula	C18H17ClN2O2
Molecular Weight	328.793
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://link.springer.com/referenceworkentry/10.1007%2F978-3-540-68706-1_1742
Curator's Comment: Description was created based on several sources, including http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1254

Oxazolam is a prodrug (precursor) for the benzodiazepine desmethyl-diazepam (nordazepam) and is itself a metabolic product of other benzodiazepines. It has anxiolytic, sedative, and anticonvulsant properties. It is a GABA-A receptor agonist. Oxazolam is marketed in Japan under the brand name Serenal. It is usually used to treat anxiety, tension, depression, and sleeping disorder in neurosis. It is used to treat somatic symptoms in psychosomatic disorders (gastrointestinal diseases, circulatory diseases, endocrine diseases, and autonomic dystonia), anxiety, tension, and depression. It is also used as a preanesthetic medication.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
benzodiazepine receptor binding 1 Target ID: GO:0030156 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2857046	Partial Agonist 290
GABA receptor alpha-1 subunit 19 Target ID: CHEMBL1962 Sources: http://www.t3db.ca/toxins/T3D4651	Agonist 2678
GABA receptor alpha-2 subunit 7 Target ID: CHEMBL4956 Sources: http://www.t3db.ca/toxins/T3D4651	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Anxiety 267 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2899329	Primary		Approved 8429	Serenal Approved Use Serenal is usually used to treat anxiety, tension, depression, and sleeping disorder in neurosis. It is used to treat somatic symptoms in psychosomatic disorders (gastrointestinal diseases, circulatory diseases, endocrine diseases, and autonomic dystonia), anxiety, tension, and depression. It is also used as a preanesthetic medication.
Depression 235 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1254	Primary		Approved 8429	Serenal Approved Use Serenal is usually used to treat anxiety, tension, depression, and sleeping disorder in neurosis. It is used to treat somatic symptoms in psychosomatic disorders (gastrointestinal diseases, circulatory diseases, endocrine diseases, and autonomic dystonia), anxiety, tension, and depression. It is also used as a preanesthetic medication.

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

General dosage regimen: For adults, take 1 to 2 tablets (10 to 20 mg of the active ingredient) at a time, 3 times daily. If you take the medicine as a preanesthetic medication, take 1 to 2 mg/kg of the active ingredient before going to bed or the surgery.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 18:02:04 GMT 2023` Edited by `admin` on `Sat Dec 16 18:02:04 GMT 2023`
Record UNII	1V2WI2NA1C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXAZOLAM

Official Name

English

TRANQUIT

Brand Name

English

oxazolam [INN]

Common Name

English

OXAZOLAM [MART.]

Common Name

English

OXAZOLAM [MI]

Common Name

English

HIALIZAN

Brand Name

English

OXAZOLAM [JAN]

Common Name

English

SERENAL

Brand Name

English

Oxazolam [WHO-DD]

Common Name

English

Classification Tree Code System Code

DEA NO.

2839